Cost-effectiveness analysis of the treatment of end-stage renal disease in Brazil.
Cost-effectiveness analysis compared four treatments of end-stage renal disease in Brazil: continuous ambulatory peritoneal dialysis (CAPD), in-center hemodialysis (HD), cadaver donor transplantation (CD-Tx), and living related donor transplantation (LR-Tx). After 2 years, the costs per year of survival were CAPD, $12,134; HD, $10,065; CD-Tx, $6,978; and LR-Tx, $3,022. The HD cost was lower than CAPD partially because of the reuse of hemodialyzers in Brazil. Although less cost-effective, both dialysis treatments yielded more years of survival after 2 years. This analysis reveals a trade-off between cost per year of survival and years of survival.
Sesso
R
R
Escola Paulista de Medicina, Disciplina de Nefrologia, São Paulo, Brazil 04023.
Eisenberg
J M
JM
Stabile
C
C
Draibe
S
S
Ajzen
H
H
Ramos
O
O
D000293:Adolescent; D000328:Adult; D001938:Brazil; D003362:Cost-Benefit Analysis; D006801:Humans; D007676:Kidney Failure, Chronic / Q000191:economics* / Q000401:mortality / Q000628:therapy; D016030:Kidney Transplantation / Q000191:economics*; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000191:economics*; D006435:Renal Dialysis / Q000191:economics*; D015996:Survival Rate